Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
Year: 2019
Type: article
Source: Journal of Cardiac Failure
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: American Heart Association, Boehringer Ingelheim, Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Merck, Novartis, Medtronic, United Therapeutics Corporation, Cytokinetics, Bayer Fund, Luitpold Pharmaceuticals, European Commission, Vifor Pharma, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, Janssen Pharmaceuticals, Actelion Pharmaceuticals
Awards: G1422855837, G1684162358, G1748529341, G1752053572, G3030831064, G3338468411, G4478086497, G4657933010, G5076495481, G516629895, G5392891041, SALsalate to Improve Exercise toleraNce and LVDD in T2dm-DHF (SALIENT-DHF trial), G5865313147, Machine learning for the automated identification and tracking of rare myocardial diseases, G61257086, G6211668631, Heart Failure Clinical Trials Network, G6830034829, Molecular Determinants of Hypertensive HFpEF: Genomics, Transcriptomics, and Proteomics, Role of Female Sex and Hormone Status on HFpEF Pathophysiology and Therapy, G9000048884, Research Training in CVD Epidemiology and Prevention, G9000077901, G9000083262, G9000090027, G9000140322, G9000251151, G9000336892
OpenAlex ID: W2995451250
